Abstract
Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.
| Original language | English |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | European Journal of Cardiovascular Prevention and Rehabilitation |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2009 |
Fingerprint
Keywords
- Bile acid sequestrant
- Cardiovascular disease
- Colesevelam hydrochloride
- Lipid lowering
- Low-density lipoprotein-cholesterol
- Nonsystemic drug
ASJC Scopus subject areas
- Medicine(all)
- Cardiology and Cardiovascular Medicine
- Epidemiology
Cite this
Colesevelam hydrochloride : Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. / Corsini, Alberto; Windler, Eberhard; Farnier, Michel.
In: European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 16, No. 1, 02.2009, p. 1-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Colesevelam hydrochloride
T2 - Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol
AU - Corsini, Alberto
AU - Windler, Eberhard
AU - Farnier, Michel
PY - 2009/2
Y1 - 2009/2
N2 - Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.
AB - Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.
KW - Bile acid sequestrant
KW - Cardiovascular disease
KW - Colesevelam hydrochloride
KW - Lipid lowering
KW - Low-density lipoprotein-cholesterol
KW - Nonsystemic drug
UR - http://www.scopus.com/inward/record.url?scp=65649114360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65649114360&partnerID=8YFLogxK
U2 - 10.1097/HJR.0b013e32831215db
DO - 10.1097/HJR.0b013e32831215db
M3 - Article
C2 - 19237992
AN - SCOPUS:65649114360
VL - 16
SP - 1
EP - 9
JO - European Journal of Cardiovascular Prevention and Rehabilitation
JF - European Journal of Cardiovascular Prevention and Rehabilitation
SN - 1741-8267
IS - 1
ER -